Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Indoco Remedies gets...

    Indoco Remedies gets USFDA warning letter for significant violations at Goa facility

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-26T09:30:04+05:30  |  Updated On 16 Aug 2021 7:48 AM GMT

    Stating the specific violations, the US Food and Drug Administration (USFDA) said Indoco Remedies failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced.


    New Delhi: The US health regulator has red-flagged significant violations of current good manufacturing practice (CGMP) regulations at drug firm Indoco Remedies' Goa facility, according to a warning letter issued by the USFDA.


    Stating the specific violations, the US Food and Drug Administration (USFDA) said the firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced.


    Pointing out another violation, the regulator said, the "firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed".


    USFDA had inspected the company's Goa facility from January 17 to 25, 2019.


    Another violation mentioned by the regulator said the firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards.


    On the data integrity remediation, the letter said, the company's "quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you (the company) manufacture".


    It strongly recommended that the company retains a qualified consultant to assist in its remediation.


    The regulator, in its letter made public on July 23, said it has reviewed the company's February 15, 2019, a response in detail and acknowledged receipt of its subsequent correspondence.


    The letter to Indoco Remedies Chairman Suresh G Kare also said that the "firm does not have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality".

    https://pubads.g.doubleclick.net/gampad/ads?iu=/21687779244/clinicalkey_video_ad&description_url=[placeholder]&tfcd=0&npa=0&sz=640x480&gdfp_req=1&output=vast&unviewed_position_start=1&env=vp&impl=s&correlator=

    The regulator also said the company was responsible for investigating these violations, for determining the causes, for preventing their recurrence, and for preventing other violations.


    "Until you correct all violations completely and we confirm your compliance with CGMP, FDA may withhold approval of any new applications or supplements listing your firm (Indoco Remedies) as a drug manufacturer," the letter said.


    In a regulatory filing on July 15 this year, Indoco Remedies had said that it had received a warning letter from the USFDA, and had said it would respond to the warning letter within a stipulated time. It, however, had not provided the details about the violations pointed out by the regulator in the letter.


    Also Read: USFDA issues warning letter to Indoco Remedies for Goa plant

    cGMP Goa plant indoco goa plant indoco inspection Indoco Remedies suresh g kare USFDA USFDA inspection USFDA warning USFDA warning letter violation 
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X